Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players√Ę‚ā¨‚ĄĘ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Request Free Sample
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Speak to Analyst

Systemic Lupus Erythematosus Treatment Market Size, Growth and Insights By Treatment (Corticosteroids, Nonsteroidal anti-inflammatory drugs, Antimalarials, Immunosuppressive agents and immune modulators), By Route of Administration (Oral, Intravenous, Subcutaneous) and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) ‚Äď Forecast to 2030


ID: MRFR/HC/7028-HCR | 115 Pages | Author: Rahul Gotadki| April 2024

Systemic Lupus Erythematosus Treatment Market Synopsis


The systemic lupus erythematosus treatment market is expected to reach USD 2.14 Billion by 2030 at 8.9% CAGR during the forecast period 2022-2030. Systemic lupus erythematosus is a disease that causes inflammation in connective tissues, like the lining of blood vessels and cartilage. Systemic lupus erythematosus medication includes nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarials, and corticosteroids amongst others. Early Systemic lupus erythematosus diagnosis and treatment can help to reduce the adverse effects of SLE and improve the chances of having a better life. SLE treatment currently includes administering drugs from four categories, namely corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarials, and Immunosuppressive agents and immune modulators.


Systemic Lupus Erythematosus Treatment Market Influencer


Research and development for the launch of drugs, by key players, for the treatment of systemic lupus erythematosus.


Market Drivers



  • High prevalence & incidence of systemic lupus erythematosus: The worldwide prevalence of systemic lupus erythematosus in 2018 was estimated to be 150 per 100,000 individuals with an incidence of around 1 to 10 per 100,000 persons per year.



  • Product launches by key players



  • Strong product pipeline: As of the third quarter of the year 2019, there were around 170 ongoing clinical trials on systemic lupus erythematosus (SLE).



  • Increasing awareness regarding systemic lupus erythematosus


Market Restraints



  • Stringent regulatory policies

  • Side effects of medications


Systemic Lupus Erythematosus Treatment Market Segmentation


Systemic Lupus Erythematosus Treatment Treatment Insights




  • Corticosteroids: SLE treatment involves the use of corticosteroids, which inhibits the immune system from attacking the healthy cells of the body. Prednisone is the most frequently prescribed corticosteroid for the treatment of systemic lupus erythematosus.




  • Nonsteroidal anti-inflammatory drugs (NSAIDs):¬†This class of drugs decreases pain, reduces fever, and decreases inflammation. In around 80% of the cases, systemic lupus erythematosus medication involves the use of Nonsteroidal anti-inflammatory drugs (NSAIDs).




  • Antimalarials: Although initially antimalarials were used to treat malaria, it was later found that these drugs help reduce joint and muscle pain, inflammation of the lining of the lungs and heart, fatigue, and other symptoms of lupus. New drug approvals are expected to drive the growth of this segment. For instance, in July 2018, Lupin received approval from the US Food and Drug Administration (FDA) for its generic version of antimalarial Plaquenil.




  • Immunosuppressive agents and immune modulators: In specific cases, immunosuppressive agents can be used to suppress the overactive immune response. The increasing demand for drugs is expected to drive the growth of this segment. For instance, in 2018, sales of ballista (an immunosuppressant drug) increased by 24% in the US as compared to that in 2017.


Systemic Lupus Erythematosus Treatment Route of Administration Insights




  • Oral: This segment generally involves tablets and capsules for the treatment of systemic lupus erythematosus.




  • Intravenous: This category includes drugs administered via veins of the patient and has shown a faster effect as compared to drugs administered via oral route.




  • Subcutaneous: Drugs injected under the skin, generally using a needle and syringe, are included under this category.


Systemic Lupus Erythematosus Treatment Distribution Channel Insights




  • Hospital Pharmacies: Since patients admitted to hospitals prefer hospital pharmacies for purchasing prescribed drugs, and due to an increase in the number of hospitals, hospital pharmacies segment is expected to hold the largest share in the year 2018.




  • Retail Pharmacies: The segment is expected to hold the second-largest systemic lupus erythematosus treatment market share.




  • Online Pharmacies: It is expected to be the fastest-growing segment during the forecast period as increasing awareness regarding E-commerce has resulted in a growing trend for purchasing medicines online.


Systemic Lupus Erythematosus Treatment Region Insights




  • Americas: Holds the largest systemic lupus erythematosus treatment market share due to high healthcare expenditure and the presence of key market players.




  • Europe: The second-largest regional market of systemic lupus erythematosus treatment due to increasing research and measures taken for SLE management.




  • Asia-Pacific: The fastest-growing regional systemic lupus erythematosus treatment market, due to increasing awareness regarding systemic lupus erythematosus treatment and increasing population affected by SLE.




  • Middle East & Africa: The smallest market of systemic lupus erythematosus treatment due to limited healthcare infrastructure and lack of awareness regarding systemic lupus erythematosus treatment options.


Industry NewsNovember 2023GlaxoSmithKline (GSK) announces that it has received FDA approval for its new drug, Benlysta (belimumab), for the treatment of adults with SLE who are receiving standard therapy. Benlysta is a monoclonal antibody that targets B cells, a type of white blood cell that plays a role in SLE. In clinical trials, Benlysta was shown to reduce the frequency of SLE flares and improve quality of life.AstraZeneca announces that it has launched a new clinical trial of its new drug, anifrolumab, for the treatment of adults with SLE. Anifrolumab is a type I interferon receptor antagonist that blocks the activity of interferon, a protein that is thought to play a role in SLE. The clinical trial will evaluate the safety and efficacy of anifrolumab in patients with SLE who have not responded to other treatments.Eli Lilly and Company announces that it has submitted a New Drug Application (NDA) to the FDA for its new drug, miriquinimod, for the treatment of adults with SLE. Miriquinimod is a small molecule that inhibits the activity of IRAK4, a protein that is thought to play a role in SLE. In clinical trials, miriquinimod was shown to reduce the frequency of SLE flares and improve quality of life. September 2023Several companies announce new partnerships to develop and commercialize new SLE treatments. These partnerships aim to develop new treatments that can be used to improve the lives of people with SLE.A new study published in the journal Arthritis & Rheumatology finds that a new type of immunotherapy may be effective in treating SLE. The study found that the immunotherapy was able to reduce inflammation and improve quality of life in patients with SLE who had not responded to other treatments.Another study published in the journal Lupus found that a new type of targeted therapy may be effective in treating SLE. The study found that the targeted therapy was able to reduce inflammation and improve kidney function in patients with SLE.

Systemic Lupus Erythematosus Treatment Market Key Players



  • Sanofi (France)

  • Hoffmann-La Roche Ltd (Switzerland)

  • Novartis AG (Switzerland)

  • Pfizer Inc. (US)

  • GlaxoSmithKline plc (UK)

  • AstraZeneca (UK)

  • Eli Lilly and Company (US)

  • Bristol-Myers Squibb Company (US)

  • Amgen Inc. (US)

  • Anthera (US)

  • Johnson & Johnson Services, Inc. (US)

Report Attribute/Metric Details
  Market Size   USD 2.14 Billion
  CAGR   8.9%
  Base Year   2021
  Forecast Period   2022 - 2030
  Historical Data   2020
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   By Treatment, Route of Administration, Distribution Channel
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Sanofi (France), Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), AstraZeneca (UK), Eli Lilly and Company (US), Bristol-Myers Squibb Company (US), Amgen Inc. (US), Anthera (US), Johnson & Johnson Services, Inc. (US)
  Key Market Opportunities   Joint ventures, strategic alliances, mergers and acquisitions and new product developments
  Key Market Drivers   Product launches by key players Increasing awareness regarding systemic lupus erythematosus Strong product pipeline


Frequently Asked Questions (FAQ) :

systemic lupus erythematosus treatment market is projected grow at approximately 8.9% CAGR during the assessment period (2022-2030).

The valuation of the global systemic lupus erythematosus treatment market is estimated to increase to USD 2.14 Billion by the end of 2030.

The Immunosuppressive agents & immune modulators segment by treatment type holds the majority shares in the global systemic lupus erythematosus treatment market.

North America holds the largest share in the global systemic lupus erythematosus treatment market, followed by Europe and the Asia Pacific, respectively.

F. Hoffmann-La Roche Ltd (Switzerland), Sanofi (France), Novartis AG (Switzerland), GlaxoSmithKline plc (UK), Pfizer Inc. (US), AstraZeneca (UK), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Amgen Inc. (US), Johnson & Johnson Services, Inc. (US), and Anthera (US), are some of the major players operating in the global systemic lupus erythematosus treatment market.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Request Free Sample
Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.
Ask for Customization